Argos Therapeutics (OTCMKTS:ARGSQ) and ASLAN Pharmaceuticals (NASDAQ:ASLN) Head to Head Survey

Valuation and Earnings

This table compares ASLAN Pharmaceuticals and Argos Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12.00 million	0.10	-$44.22 million	($21.92)	-0.03
Argos Therapeutics	$1.90 million	0.30	-$40.57 million	N/A	N/A

Argos Therapeutics has lower revenue, but higher earnings than ASLAN Pharmaceuticals.

Profitability

This table compares ASLAN Pharmaceuticals and Argos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
Argos Therapeutics	N/A	N/A	N/A

Insider and Institutional Ownership

58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by company insiders. Comparatively, 28.2% of Argos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

ASLAN Pharmaceuticals has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Argos Therapeutics has a beta of 2.47, suggesting that its share price is 147% more volatile than the S&P 500.

Summary

Argos Therapeutics beats ASLAN Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

About Argos Therapeutics

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.